Abstract: The present invention provides a medium chain fatty acid (MCFA) for use in treating and/or preventing anxiety.

Abstract: The present invention provides a medium chain fatty acid (MCFA) for use in treating and/or preventing anxiety.

Abstract: A device comprising a plurality of sample wells wherein the device has a plurality of compartments, each compartment surrounding at least one well. The compartments are defined by compartment wall means. The compartment wall means may be associated with at least one well or the compartment wall means may be associated with a group of wells. The compartment may house an environmental buffering system.

Abstract: A device (1) for housing a scientific sample comprising at least one sample well (2) and an on-board buffering substance (3) wherein the onboard buffering substance (3) at least partly surrounds the sample well (2). The on-board buffering substance (3) may be in the form of a matrix, such as a gel-like matrix. The device (1) may further comprise an insulating means. Also described is a substance for use in culturing and/or assaying a sample whereby the substance provides atmospheric and thermal buffering. The invention further provides a lid for a single-well or multi-well sample plate, the lid being configured to facilitate delivery of a sample through the lid into a well, and for sealing the well. The lid comprises moveable portions (52, 53) that have at least one orifice (54, 57) formed through the moveable portions (52, 53) such that a conduit is formed by alignment of the orifices (54, 57) of both the lid portions (52, 53).

Abstract: A frozen confection or a beverage product is provided which contains at least 400 mg of theobromine and at least 40 mg of caffeine per 100 grams of the product. Also provided is a frozen confection or a beverage product for the enhancement of mood without transient elevation of blood pressure.

Abstract: A method for quantitatively and qualitatively determining the presence of a macromolecule comprises providing nanoparticles in a buffered solution, adding a test sample to the buffered nanoparticle solution, and measuring the difference between the buffered nanoparticles in the presence and absence of the test sample. The nanoparticles are preferably less than 100 nm in size.

Abstract: Therapeutic drug delivery and diagnostics systems comprise biologically active compounds associated with particulate carriers of less than 20 nm. These systems can be utilised for targeted modification of growth, development and functions, such as gene expression, protein synthesis, intracellular energy production and transport mechanisms in prokaryotic and eukaryotic organisms. The systems are also applicable for controlled modification of structural and functional properties of extracellular components and tissue constituents. The characteristics of a biological site are evaluated and an entity is provided which is dependent on the site characteristics. The entity comprises nanoparticles of less than 20 nm. A probe comprising nanoparticles of less than 5 nm is also provided.